Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Published version of a preprint

Abstract

The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a prospective observational study by the German Cancer Consortium that applies whole-genome/exome and RNA sequencing to inform the care of adults with incurable cancers. On the basis of 472 single and six composite biomarkers, a cross-institutional molecular tumor board provided evidence-based management recommendations, including diagnostic reevaluation, genetic counseling, and experimental treatment, in 88% of cases. Recommended therapies were administered in 362 of 1,138 patients (31.8%) and resulted in significantly improved overall response and disease control rates (23.9% and 55.3%) compared with previous therapies, translating into a progression-free survival ratio >1.3 in 35.7% of patients. These data demonstrate the benefit of molecular stratification in rare cancers and represent a resource that may promote clinical trial access and drug approvals in this underserved patient population. SIGNIFICANCE: Rare cancers are difficult to treat; in particular, molecular pathogenesis-oriented medical therapies are often lacking. This study shows that whole-genome/exome and RNA sequencing enables molecularly informed treatments that lead to clinical benefit in a substantial proportion of patients with advanced rare cancers and paves the way for future clinical trials. See rela…

Overview

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-0126

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 51 references

Cited by

See all 290

Metadata

Authors
Horak, P., Heining, C., Kreutzfeldt, S., Hutter, B., Mock, A., Hüllein, J., Fröhlich, M., Uhrig, S., Jahn, A., Rump, A., Gieldon, L., Möhrmann, L., Hanf, D., Teleanu, V., Heilig, C. E., Lipka, D. B., Allgäuer, M., Ruhnke, L., Laßmann, A., Endris, V., Neumann, O., Penzel, R., Beck, K., Richter, D., Winter, U., Wolf, S., Pfütze, K., Geörg, C., Meißburger, B., Buchhalter, I., Augustin, M., Aulitzky, W. E., Hohenberger, P., Kroiss, M., Schirmacher, P., Schlenk, R. F., Keilholz, U., Klauschen, F., Folprecht, G., Bauer, S., Siveke, J. T., Brandts, C. H., Kindler, T., Boerries, M., Illert, A. L., von Bubnoff, N., Jost, P. J., Spiekermann, K., Bitzer, M., Schulze-Osthoff, K., von Kalle, C., Klink, B., Brors, B., Stenzinger, A., Schröck, E., Hübschmann, D., Weichert, W., Glimm, H., & Fröhling, S.
Affiliations
  • German Cancer Research Center (DE)
  • University Hospital Carl Gustav Carus (DE)
  • 1Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • University Hospital Heidelberg (DE)
  • Nuremberg Hospital (DE)
  • Robert Bosch Hospital (DE)
  • Heidelberg University (DE)
  • University of Würzburg (DE)
  • Charité – Universitätsmedizin Berlin (DE)
  • Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
  • Essen University Hospital (DE)
  • Goethe University Frankfurt (DE)
  • Johannes Gutenberg University Mainz (DE)
  • University of Freiburg (DE)
  • Medical University of Graz (AT)
  • Ludwig-Maximilians-Universität München (DE)
  • Universitätsklinikum Tübingen (DE)
  • 49DKTK, Tübingen, Germany.
  • 51Clinical Study Center, Charité – Universitätsmedizin Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Luxembourg Institute of Health (LU)
  • Technical University of Munich (DE)
Corresponding author
  • Glimm, Hanno
  • Fröhling, Stefan
Venue
Cancer Discovery
Published
2021-06-10
Volume
11
Issue
11
Pages
2780-2795
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3171689169
Cited by
290
References
51
Citations by year
2026: 49 · 2025: 57 · 2024: 54 · 2023: 67 · 2022: 50 · 2021: 12
FWCI
18.18
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders
German Cancer Research Center (H021)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
rare tumor, molecular profiling, molecular tumor board, targeted therapy, biomarkers, molecular stratification, clinical decision-making, progression-free survival, clinical trial access, genetic counseling, advanced cancer
MeSH terms
Exome Sequencing, Adult, Humans, Neoplasms, Gene Expression Profiling, Genomics, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-0126
The paper
Horak, P., Heining, C., Kreutzfeldt, S., Hutter, B., Mock, A., Hüllein, J., Fröhlich, M., Uhrig, S., Jahn, A., Rump, A., Gieldon, L., Möhrmann, L., Hanf, D., Teleanu, V., Heilig, C. E., Lipka, D. B., Allgäuer, M., Ruhnke, L., Laßmann, A., . . . Fröhling, S. (2021). Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-0126

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.